Aquaporin Launches Major Capital Raise to Power Water Technology Growth
December 21, 2025, 9:33 am
Aquaporin initiates a DKK 78 million rights issue. The water technology firm urgently needs capital by early 2026. Funds will support ongoing operations and accelerate crucial development of second-generation filtration technology. This strategic move aims for mid-term profitability and ambitious long-term revenue growth. Failure to secure sufficient capital poses a significant "going concern" risk. The company remains committed to its biotech-driven water filtration solutions, addressing global water scarcity and quality challenges through innovation and strategic investment.
Aquaporin, a leader in innovative water technology, announced a significant capital raise. The company will execute a rights issue. It seeks up to DKK 78 million. This funding is critical. It ensures continued operations. It drives future growth initiatives.
The company requires additional capital from early 2026. This is a direct outcome of its current financial position. A thorough strategic review confirmed this need. The Board of Directors authorized the rights issue. Shareholder approval preceded this decision.
The rights issue offers up to 77,536,770 new shares. Each share costs DKK 1. This could inject approximately DKK 78 million into Aquaporin. Existing shareholders receive pre-emptive rights. The subscription ratio is 10:3. Ten existing shares yield rights to three new shares.
Dilution is a factor. Shareholders not participating face significant dilution. It could reach up to 77 percent. This underscores the importance of the offering for current investors.
Proceeds from the rights issue have clear objectives. Primarily, they will finance operations. They cover the company's cost base for 2026. A substantial portion funds key research and development. This includes the second-generation Aquaporin Inside® technology. This technology, known as AiG2, represents the future.
Aquaporin plans to commercialize AiG2 in 2027 and 2028. This next-gen technology promises increased efficiency. It will enhance Reverse Osmosis products. It also aims to unlock Forward Osmosis at an industrial scale. This is a critical step for market expansion.
The rights issue provides short-term funding flexibility. It covers capital requirements through the second quarter of 2027. However, more capital may be necessary beyond this period. The company targets mid-term profitability. Its current business plan depends on successful funding.
Financial targets are ambitious. Aquaporin expects to double its revenue in 2026. This compares to its 2025 revenue. EBITDA, before special items, projects a loss of DKK (40)-(50) million for 2026. This guidance assumes successful rights issue completion. It also relies on revenue growth in Residential Drinking Water and Forward Osmosis. A stable cost base is also assumed.
Mid-term strategy focuses on profitability. Aquaporin aims for group-level profitability. It targets EBITDA break-even. This should occur towards the end of the mid-term period. Revenue growth is a key driver. The company expects an average annual growth rate in the mid-double-digit range. This will stabilize around 25 percent long-term.
Gross margins will improve. Aquaporin targets the lower-to-mid double-digit range. This shift in product mix and cost-competitive outsourcing supports these gains. The AiG2 launch is also pivotal for margin improvement.
Long-term aspirations are bold. Beyond ten years, Aquaporin envisions DKK 1 billion in revenue. It targets further gross margin improvements from scaling. A double-digit EBITDA margin is the ultimate goal.
All three business segments will contribute to this growth. Industrial Water, Forward Osmosis, and Residential Drinking Water are all vital. AiG2-based solutions will increasingly drive growth. This impact will be particularly strong in Industrial Water and Forward Osmosis segments.
Cost control remains paramount. Operating expenses and organizational size will stay near current levels mid-term. R&D investments will also maintain current levels. After achieving profitability, working capital requirements will increase. OPEX will then rise by approximately 10 percent annually.
A critical risk exists. If the rights issue fails, severe consequences loom. Gross proceeds significantly less than DKK 78 million create material uncertainty. The company's "going concern" status could be jeopardized. This would force substantial business plan changes. Cost reductions or asset divestments might follow. Alternative funding, sooner than expected, would be necessary.
Support for the offering exists. Certain existing shareholders made advance commitments. Major investors like M. Goldschmidt Capital A/S and VP Capital N.V. provided pre-subscription and guarantee commitments. These total up to DKK 20.7 million. Members of the Board and Executive Management also committed DKK 0.9 million. These commitments cover up to 27.9 percent of the maximum shares offered.
The rights trading period runs from January 5, 2026, to January 16, 2026. The subscription period follows. It begins on January 7, 2026, and closes on January 20, 2026. New shares will be admitted to trading on Nasdaq Copenhagen by January 28, 2026.
Aquaporin operates globally. Its headquarters are in Denmark. Operations span Singapore, Turkey, the United States, and China. The company uses biotechnology. It rethinks water filtration. Its unique Aquaporin Inside® technology forms the core of its solutions. This Nobel Prize-winning research technology is deployed across industries. It serves homes. NASA even utilizes it in space. Aquaporin partners globally. It treats industrial wastewater. It concentrates food and beverage products naturally. It enhances drinking water quality and accessibility.
This capital raise is a strategic imperative. It secures immediate operations. It funds critical innovation. It lays the groundwork for Aquaporin's ambitious future in water technology. Success depends on shareholder confidence and market execution.
Aquaporin, a leader in innovative water technology, announced a significant capital raise. The company will execute a rights issue. It seeks up to DKK 78 million. This funding is critical. It ensures continued operations. It drives future growth initiatives.
The company requires additional capital from early 2026. This is a direct outcome of its current financial position. A thorough strategic review confirmed this need. The Board of Directors authorized the rights issue. Shareholder approval preceded this decision.
The rights issue offers up to 77,536,770 new shares. Each share costs DKK 1. This could inject approximately DKK 78 million into Aquaporin. Existing shareholders receive pre-emptive rights. The subscription ratio is 10:3. Ten existing shares yield rights to three new shares.
Dilution is a factor. Shareholders not participating face significant dilution. It could reach up to 77 percent. This underscores the importance of the offering for current investors.
Proceeds from the rights issue have clear objectives. Primarily, they will finance operations. They cover the company's cost base for 2026. A substantial portion funds key research and development. This includes the second-generation Aquaporin Inside® technology. This technology, known as AiG2, represents the future.
Aquaporin plans to commercialize AiG2 in 2027 and 2028. This next-gen technology promises increased efficiency. It will enhance Reverse Osmosis products. It also aims to unlock Forward Osmosis at an industrial scale. This is a critical step for market expansion.
The rights issue provides short-term funding flexibility. It covers capital requirements through the second quarter of 2027. However, more capital may be necessary beyond this period. The company targets mid-term profitability. Its current business plan depends on successful funding.
Financial targets are ambitious. Aquaporin expects to double its revenue in 2026. This compares to its 2025 revenue. EBITDA, before special items, projects a loss of DKK (40)-(50) million for 2026. This guidance assumes successful rights issue completion. It also relies on revenue growth in Residential Drinking Water and Forward Osmosis. A stable cost base is also assumed.
Mid-term strategy focuses on profitability. Aquaporin aims for group-level profitability. It targets EBITDA break-even. This should occur towards the end of the mid-term period. Revenue growth is a key driver. The company expects an average annual growth rate in the mid-double-digit range. This will stabilize around 25 percent long-term.
Gross margins will improve. Aquaporin targets the lower-to-mid double-digit range. This shift in product mix and cost-competitive outsourcing supports these gains. The AiG2 launch is also pivotal for margin improvement.
Long-term aspirations are bold. Beyond ten years, Aquaporin envisions DKK 1 billion in revenue. It targets further gross margin improvements from scaling. A double-digit EBITDA margin is the ultimate goal.
All three business segments will contribute to this growth. Industrial Water, Forward Osmosis, and Residential Drinking Water are all vital. AiG2-based solutions will increasingly drive growth. This impact will be particularly strong in Industrial Water and Forward Osmosis segments.
Cost control remains paramount. Operating expenses and organizational size will stay near current levels mid-term. R&D investments will also maintain current levels. After achieving profitability, working capital requirements will increase. OPEX will then rise by approximately 10 percent annually.
A critical risk exists. If the rights issue fails, severe consequences loom. Gross proceeds significantly less than DKK 78 million create material uncertainty. The company's "going concern" status could be jeopardized. This would force substantial business plan changes. Cost reductions or asset divestments might follow. Alternative funding, sooner than expected, would be necessary.
Support for the offering exists. Certain existing shareholders made advance commitments. Major investors like M. Goldschmidt Capital A/S and VP Capital N.V. provided pre-subscription and guarantee commitments. These total up to DKK 20.7 million. Members of the Board and Executive Management also committed DKK 0.9 million. These commitments cover up to 27.9 percent of the maximum shares offered.
The rights trading period runs from January 5, 2026, to January 16, 2026. The subscription period follows. It begins on January 7, 2026, and closes on January 20, 2026. New shares will be admitted to trading on Nasdaq Copenhagen by January 28, 2026.
Aquaporin operates globally. Its headquarters are in Denmark. Operations span Singapore, Turkey, the United States, and China. The company uses biotechnology. It rethinks water filtration. Its unique Aquaporin Inside® technology forms the core of its solutions. This Nobel Prize-winning research technology is deployed across industries. It serves homes. NASA even utilizes it in space. Aquaporin partners globally. It treats industrial wastewater. It concentrates food and beverage products naturally. It enhances drinking water quality and accessibility.
This capital raise is a strategic imperative. It secures immediate operations. It funds critical innovation. It lays the groundwork for Aquaporin's ambitious future in water technology. Success depends on shareholder confidence and market execution.